Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Daiichi Sankyo
Federal Trade Commission
Citi
US Army
Healthtrust
Farmers Insurance
McKesson
Medtronic
QuintilesIMS

Generated: August 22, 2017

DrugPatentWatch Database Preview

DUEXIS Drug Profile

« Back to Dashboard

Which patents cover Duexis, and what generic Duexis alternatives are available?

Duexis is a drug marketed by Horizon Pharma and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-two patent family members in fourteen countries.

The generic ingredient in DUEXIS is famotidine; ibuprofen. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the famotidine; ibuprofen profile page.

Summary for Tradename: DUEXIS

Patents:6
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list1
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:DUEXIS at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Horizon Pharma
DUEXIS
famotidine; ibuprofen
TABLET;ORAL022519-001Apr 23, 2011RXYesYes► Subscribe► SubscribeY ► Subscribe
Horizon Pharma
DUEXIS
famotidine; ibuprofen
TABLET;ORAL022519-001Apr 23, 2011RXYesYes► Subscribe► SubscribeY ► Subscribe
Horizon Pharma
DUEXIS
famotidine; ibuprofen
TABLET;ORAL022519-001Apr 23, 2011RXYesYes► Subscribe► SubscribeY ► Subscribe
Horizon Pharma
DUEXIS
famotidine; ibuprofen
TABLET;ORAL022519-001Apr 23, 2011RXYesYes► Subscribe► SubscribeY ► Subscribe
Horizon Pharma
DUEXIS
famotidine; ibuprofen
TABLET;ORAL022519-001Apr 23, 2011RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: DUEXIS

Drugname Dosage Strength RLD Submissiondate
ibuprofen and famotidineTablets800 mg/26.6 mgDuexis12/6/2011

International Patent Family for Tradename: DUEXIS

Country Document Number Estimated Expiration
Australia2006269894► Subscribe
European Patent Office1919288► Subscribe
China101257800► Subscribe
Israel196425► Subscribe
World Intellectual Property Organization (WIPO)2008011426► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Dow
US Army
Julphar
Queensland Health
Mallinckrodt
Accenture
Cantor Fitzgerald
Cerilliant
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot